Last reviewed · How we verify
Zontivity (VORAPAXAR)
Zontivity (VORAPAXAR) is a small molecule protease-activated receptor-1 antagonist developed by Merck Sharp Dohme and currently owned by Key Therap. It targets the proteinase-activated receptor 1 to prevent blood clots and is approved for the prevention of myocardial infarction and cerebrovascular accidents. Zontivity was FDA-approved in 2014 and has a long half-life of 149 hours. The commercial status of Zontivity is patented, with no generic manufacturers available. Key safety considerations include its potential to increase the risk of bleeding.
At a glance
| Generic name | VORAPAXAR |
|---|---|
| Sponsor | Key Therap |
| Drug class | Protease-activated Receptor-1 Antagonist |
| Target | Proteinase-activated receptor 1 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 2014 |
Approved indications
- Cerebrovascular accident
- Myocardial Infarction Prevention
Common side effects
Key clinical trials
- Vorapaxar on Thrombin Generation and Coagulability (PHASE4)
- Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor (PHASE4)
- Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus (PHASE4)
- Vorapaxar in the Human Endotoxemia Model (PHASE4)
- Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints (PHASE1,PHASE2)
- Vorapaxar Study for Maturation of AV Fistulae for Hemodialysis Access (PHASE2)
- Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183) (PHASE3)
- Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017) (PHASE2)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zontivity CI brief — competitive landscape report
- Zontivity updates RSS · CI watch RSS
- Key Therap portfolio CI